Based on 784 businesses audited.
Medical Devices, Pharma & Biotech Reputation: Organovo, Inc. (organovo.com)
Organovo presents a classic Biotech time-capsule: high technical promise and specific pipeline terminology undermined by a total lack of updated evidence and technical schema. The gap between its 2025 milestones and the current 2026 date suggests a company whose digital presence has stalled while its Nasdaq status remains under pressure.
Medical Devices, Pharma & Biotech Reputation: Organovo, Inc. (organovo.com)
The site content strongly aligns with the Pharma & Biotech industry, specifically focusing on 3D bioprinting and therapeutic pipeline development for inflammatory bowel diseases. The mention of Nasdaq listing requirements and FDA clinical trial authorizations confirms this is a high-stakes regulated entity.
“The score of 49 is primarily driven by Trust and Proof failures (specifically the 0 proof links vs 2 reviews) and Identity/Authority gaps in the technical implementation. While the Pipeline substance is superior to generic marketing sites, the temporal decay (unmet 2025 milestones) and the hollow About page prevent a lower BS score.”